Shin-Ichi Harashima

Shin-Ichi Harashima

Auto-generated profile, based on publicly available information

Shin-Ichi Harashima

Department of Chronic Care Nursing, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
ANAkiko Nishimura
Akiko Nishimura
SHShin-Ichi Harashima
Shin-Ichi Harashima
KHKiminori Hosoda
Kiminori Hosoda
HAHidenori Arai
Hidenori Arai
NINobuya Inagaki
Nobuya Inagaki
Background: This cross-sectional study aimed to describe sex-related differences in diabetes-specific factors underlying the development of frailty in older persons with type 2 diabetes. Methods: Older persons aged 60–80 years were sequentially enrolled. Frailty and sarcopenia were evaluated using the validated Kihon checklist (KCL) and Asian Working Group for Sarcopenia algorithm, respectively. Physical function and characteristics were measured by trained nurses independently. Results: This study included 213 participants. The mean age, body mass index (BMI), and glycated hemoglobin (HbA1c) level were 70.4 years, 24.3 kg/m2, and 7.4%, respectively. Prevalence of frailty was higher in women. Social and cognitive functions were lower in the prefrailty stage, while physical function was lower in the frailty stage, although there was no decrease in skeletal muscle mass. After adjustment for age, the KCL score was significantly associated with peripheral neuropathy, diet score, and coronary artery disease (CAD); frailty, with CAD and inoccupation; prefrailty, with diet score; and sarcopenia, with living alone in men. Meanwhile, the KCL score was significantly associated with living alone and skeletal muscle percentage; prefrailty, with peripheral neuropathy; and sarcopenia, with diabetes duration, LDL-cholesterol level, diet score, and irregular lifestyle in women. Conclusions: Sex differences in the risk factors of frailty should be considered when selecting preventive strategies for older persons with type 2 diabetes, early in the prefrailty stage. In particular, it is important to evaluate social participation and diet therapy in men and skeletal muscle mass and psychosocial function in women.

8 January 2013 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
SHShin‐Ichi Harashima
Shin‐Ichi Harashima
TFToru Fukushima
Toru Fukushima
MSMayumi Sasaki
Mayumi Sasaki
YNYuichi Nishi
Yuichi Nishi
SFShimpei Fujimoto
Shimpei Fujimoto
NINobuya Inagaki
Nobuya Inagaki

12 September 2014 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
SHShin-Ichi Harashima
Shin-Ichi Harashima
ANAkiko Nishimura
Akiko Nishimura
TOTomoaki Osugi
Tomoaki Osugi
YWYu Wang
Yu Wang
YLYanyan Liu
Yanyan Liu
NINobuya Inagaki
Nobuya Inagaki
Objective We investigated the prevalence of restless legs syndrome (RLS) in Japanese patients with type 2 diabetes and assessed the efficacy of pramipexole therapy. Design One hundred patients with type 2 diabetes without secondary causes of RLS were sequentially screened for the 12-week, prospective, single arm study. RLS was screened by essential diagnostic criteria developed by the International Restless Legs Study Group. Diabetic neuropathy was diagnosed by nerve conductance study. Severity of RLS and sleep quality were assessed by the International Restless Legs Rating Scale (IRLS) and the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J), respectively. Pramipexole was administered for 12 weeks. The primary end point was change in the IRLS score in 12 weeks and secondary end points were change in PSQI-J and glycated haemoglobin (HbA1c) in 12 weeks. Results RLS was diagnosed in 8 of 100 participants (8%). Diabetic neuropathy was most likely associated with RLS (OR 3.81, 95% CI 0.85 to 17.05, p=0.111). The IRLS score was improved from 19.0±5.6 to 5.4±4.8 by pramipexole in 12 weeks (p<0.001). The change in the score was −13.6 (95% CI −15.5 to −11.7; p<0.05). PSQI-J was improved from 6.0±4.4 to 1.5±1.3 in 12 weeks (p<0.05). Change in PSQI-J was −4.5 (95% CI −6.8 to −2.1; p<0.05). HbA1c was slightly decreased from 7.19±0.56% (55±6 mmol/mol) to 6.90±0.48% (52±5 mmol/mol) in 12 weeks (p<0.05). Change in HbA1c was −0.29% (−3 mmol/mol) (95% CI −0.37% to −0.20% (−4 to −2 mmol/mol;) p<0.05). Conclusions We find that type 2 diabetes is a possible risk factor for RLS in the Japanese population, and that pramipexole treatment can improve the symptoms of RLS as well as the quality of sleep and glycaemic control in these patients. Trial registration number University hospital Medical Information Network in Japan (UMIN000008347).

5 December 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
NINobuya Inagaki
Nobuya Inagaki
SHShin‐Ichi Harashima
Shin‐Ichi Harashima
KKKohei Kaku
Kohei Kaku
KKKazuoki Kondo
Kazuoki Kondo
NMNobuko Maruyama
Nobuko Maruyama
HIHiroaki Iijima
Hiroaki Iijima
Aim: The aim of this study was to assess the long‐term efficacy and safety of canagliflozin as add‐on therapy in Japanese patients with type 2 diabetes mellitus who had inadequate glycaemic control with insulin. Materials and methods: The study comprised a 16‐week, double‐blind period in which patients were randomized to either placebo (P; N = 70) or canagliflozin (100 mg, CAN; N = 76), followed by a 36‐week open‐label period in which all patients received canagliflozin. The efficacy endpoints included the change in HbA1c from baseline to end of treatment. The safety endpoints were adverse events, hypoglycaemic events, and laboratory test values. Results: The changes from baseline (mean ± standard deviation, last observation carried forward) in the P/CAN and CAN/CAN groups, respectively, were −1.09% ± 0.85% and −0.88% ± 0.86% for HbA1c, −1.40% ± 2.54% and −2.14% ± 2.75% for body weight, and 7.84% ± 14.37% and 8.91% ± 10.80% for HOMA2‐%B (all, P < .001). Adverse events occurred in 85.1% of the P/CAN group and 92.0% of the CAN/CAN group. Hypoglycaemic events occurred in 43.3% and 54.7%, respectively. All hypoglycaemic events were mild in severity and insulin dose reduction decreased the incidence rate of hypoglycaemic events. Post‐hoc ordinal logistic modelling/logistic modelling showed that lower serum C‐peptide at Week 0 was a risk factor for hypoglycaemia in both the P and CAN groups in the double‐blind period as well as in the canagliflozin all‐treatment period. Conclusions: This study demonstrates the long‐term efficacy and safety of canagliflozin combined with insulin in Japanese patients.

25 May 2024 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
ANAkiko Nishimura
Akiko Nishimura
CMChie Masuda
Chie Masuda
CMChiyo Murauchi
Chiyo Murauchi
MIMiho Ishii
Miho Ishii
YMYuko Murata
Yuko Murata
SHShin-Ichi Harashima
Shin-Ichi Harashima
Background Older adults with diabetes mellitus require drug treatment considering their frailty, cognitive function, and hypoglycemia. Objective We investigated the association between diabetic pharmacologic therapy and both diabetic complications and frailty across eight diabetes-specific outpatient clinics nationwide. Methods Participants (aged 60–80 years) who had type 2 diabetes and did not require nursing care were included in the study. Basic attributes, patient background, complications, hypoglycemic status, body weight, body composition, blood tests, grip strength, and Kihon Checklist (a frailty index) and self-care scores were obtained. Descriptive statistics, t-test, chi-square test, and regression analyses were employed for evaluation. Results Overall, 417 participants were included (224 men, 193 women, mean age 70.1 ± 5.4 years, diabetes duration 14.9 ± 10.9 years, body mass index 24.5 ± 3.8, glycated hemoglobin 7.22 ± 0.98%, proportion of individuals with frailty and prefrailty, 19.9% and 41.0%, respectively). All drugs were used more frequently in prefrailty conditions. Each diabetes medication was related to complications, body composition, and frailty, as follows: sulfonylurea (lower hypoglycemia); glinide (severe hypoglycemia, retinopathy, weaker grip strength, high Kihon Checklist score, decreased physical activities); alpha-glucosidase inhibitors (no association); biguanide (high body mass index, high body fat, stronger grip strength); thiazolidinedione (decreased instrumental activities of daily living); dipeptidyl‐peptidase‐4 inhibitors (no association); sodium-glucose cotransporter 2 inhibitors; retinopathy, high body mass index and Kihon Checklist score, and depressive mood); glucagon-like peptide-1 receptor agonists (high body mass index and body fat and poor nutritional status); and insulin preparations (hypoglycemia, retinopathy, neuropathy, nephropathy, cardiovascular diseases, weaker grip strength, and high Kihon Checklist score and physical inactivity). Conclusions Some formulations, such as glinide, sodium-glucose cotransporter 2 inhibitors, and insulin, are associated with an increased frequency of frailty, warranting careful and individualized diabetes treatment.

19 April 2019 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
AOAyako Oshima
Ayako Oshima
ANAkiko Nishimura
Akiko Nishimura
TCToyofumi F. Chen‐Yoshikawa
Toyofumi F. Chen‐Yoshikawa
SHShin‐Ichi Harashima
Shin‐Ichi Harashima
TKTeruya Komatsu
Teruya Komatsu
NINobuya Inagaki
Nobuya Inagaki